Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alisporivir + EDP239
- Development stage
- Unknown
- Lead developer
- Enanta Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**alisporivir + EDP239** is a combination of two antiviral agents under investigation for the treatment of chronic hepatitis C virus (HCV) infection. **Alisporivir** (DEB025) is a host-targeting antiviral (HTA) and cyclophilin inhibitor that blocks HCV replication by targeting host proteins necessary for viral replication and shows pangenotypic activity with a high barrier to resistance. **EDP239** is a direct-acting antiviral (DAA), specifically an NS5A inhibitor, directly inhibiting the hepatitis C virus NS5A protein, essential for viral replication. In preclinical and early clinical studies, the combination demonstrated additive to synergistic effects in suppressing HCV replication and reduced the development of resistance, supporting its development as a next-generation, interferon-free regimen for HCV[3][5][1].
- Other names
- alisporivir + EDP239DEB025 + EDP239
02
Targets
PPIA (Peptidyl-prolyl cis-trans isomerase A)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on alisporivir + EDP239.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alisporivir + EDP239.